ARRY
Price
$9.12
Change
+$0.09 (+1.00%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
1.39B
70 days until earnings call
CHRS
Price
$1.18
Change
+$0.03 (+2.63%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
137.15M
74 days until earnings call
Interact to see
Advertisement

ARRY vs CHRS

Header iconARRY vs CHRS Comparison
Open Charts ARRY vs CHRSBanner chart's image
Array Technologies
Price$9.12
Change+$0.09 (+1.00%)
Volume$55.97K
Capitalization1.39B
Coherus Oncology
Price$1.18
Change+$0.03 (+2.63%)
Volume$800
Capitalization137.15M
ARRY vs CHRS Comparison Chart in %
Loading...
ARRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARRY vs. CHRS commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARRY is a Buy and CHRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (ARRY: $9.03 vs. CHRS: $1.14)
Brand notoriety: ARRY and CHRS are both not notable
ARRY represents the Alternative Power Generation, while CHRS is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARRY: 63% vs. CHRS: 62%
Market capitalization -- ARRY: $1.39B vs. CHRS: $137.15M
ARRY [@Alternative Power Generation] is valued at $1.39B. CHRS’s [@Biotechnology] market capitalization is $137.15M. The market cap for tickers in the [@Alternative Power Generation] industry ranges from $118.24B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Alternative Power Generation] industry is $1.85B. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARRY’s FA Score shows that 1 FA rating(s) are green whileCHRS’s FA Score has 2 green FA rating(s).

  • ARRY’s FA Score: 1 green, 4 red.
  • CHRS’s FA Score: 2 green, 3 red.
According to our system of comparison, CHRS is a better buy in the long-term than ARRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARRY’s TA Score shows that 5 TA indicator(s) are bullish while CHRS’s TA Score has 5 bullish TA indicator(s).

  • ARRY’s TA Score: 5 bullish, 5 bearish.
  • CHRS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than ARRY.

Price Growth

ARRY (@Alternative Power Generation) experienced а +1.12% price change this week, while CHRS (@Biotechnology) price change was +6.54% for the same time period.

The average weekly price growth across all stocks in the @Alternative Power Generation industry was +1.16%. For the same industry, the average monthly price growth was +4.06%, and the average quarterly price growth was +40.53%.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.10%. For the same industry, the average monthly price growth was +14.72%, and the average quarterly price growth was +30.35%.

Reported Earning Dates

ARRY is expected to report earnings on Nov 06, 2025.

CHRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Alternative Power Generation (+1.16% weekly)

The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.

@Biotechnology (+2.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARRY($1.39B) has a higher market cap than CHRS($137M). ARRY has higher P/E ratio than CHRS: ARRY (56.91) vs CHRS (2.23). ARRY YTD gains are higher at: 49.503 vs. CHRS (-17.391). CHRS has higher annual earnings (EBITDA): 88.2M vs. ARRY (-127.81M). ARRY has more cash in the bank: 377M vs. CHRS (238M). CHRS has less debt than ARRY: CHRS (41M) vs ARRY (694M). ARRY has higher revenues than CHRS: ARRY (1.17B) vs CHRS (272M).
ARRYCHRSARRY / CHRS
Capitalization1.39B137M1,015%
EBITDA-127.81M88.2M-145%
Gain YTD49.503-17.391-285%
P/E Ratio56.912.232,556%
Revenue1.17B272M431%
Total Cash377M238M158%
Total Debt694M41M1,693%
FUNDAMENTALS RATINGS
ARRY vs CHRS: Fundamental Ratings
ARRY
CHRS
OUTLOOK RATING
1..100
2211
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1005
PRICE GROWTH RATING
1..100
3746
P/E GROWTH RATING
1..100
2794
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHRS's Valuation (25) in the Biotechnology industry is significantly better than the same rating for ARRY (93). This means that CHRS’s stock grew significantly faster than ARRY’s over the last 12 months.

CHRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARRY (100). This means that CHRS’s stock grew similarly to ARRY’s over the last 12 months.

CHRS's SMR Rating (5) in the Biotechnology industry is significantly better than the same rating for ARRY (100). This means that CHRS’s stock grew significantly faster than ARRY’s over the last 12 months.

ARRY's Price Growth Rating (37) in the Biotechnology industry is in the same range as CHRS (46). This means that ARRY’s stock grew similarly to CHRS’s over the last 12 months.

ARRY's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for CHRS (94). This means that ARRY’s stock grew significantly faster than CHRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARRYCHRS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 7 days ago
72%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ARRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEMFX36.20N/A
N/A
MFS Emerging Markets Equity R2
MLPFX8.94N/A
N/A
Invesco SteelPath MLP Select 40 A
NEAMX34.58N/A
N/A
Neiman Large Cap Value A
SRUIX15.00N/A
N/A
Meeder Spectrum Institutional
BGAKX18.54-0.04
-0.22%
Baillie Gifford Global Alpha Equities K

ARRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARRY has been loosely correlated with NXT. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if ARRY jumps, then NXT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARRY
1D Price
Change %
ARRY100%
-5.54%
NXT - ARRY
63%
Loosely correlated
-1.30%
RUN - ARRY
57%
Loosely correlated
-4.88%
FSLR - ARRY
57%
Loosely correlated
-2.79%
SHLS - ARRY
55%
Loosely correlated
-4.97%
CSIQ - ARRY
54%
Loosely correlated
-9.22%
More

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+0.88%
XENE - CHRS
41%
Loosely correlated
+0.57%
ADCT - CHRS
39%
Loosely correlated
+1.58%
ARRY - CHRS
39%
Loosely correlated
-5.54%
AXON - CHRS
38%
Loosely correlated
+0.09%
XNCR - CHRS
35%
Loosely correlated
+1.52%
More